Nunn Jason Raleigh 4

What Happened
Jason Raleigh Nunn, a director of Zenas BioPharma, was granted 18,500 derivative share awards on June 15, 2026. The Form 4 (filed June 17, 2026) reports an acquisition at $0.00 per share (transaction code A — award/grant). No cash was paid in this reported grant; the award’s economic value will depend on future share price and vesting.

Key Details

• Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely filing).
• Transaction type/code: Grant/Award (A) of derivative securities.
• Amount: 18,500 underlying shares reported as acquired at $0.00 (reported value $0).
• Vesting: Footnote F1 — vests 100% on June 15, 2027 (first anniversary of vesting commencement), subject to continued service.
• Shares owned after transaction: not specified in the provided filing.
• Not an open-market purchase or sale; this is a compensation equity grant, not an immediate cash transaction.

Context
This filing documents a compensation award (derivative equity such as stock options or RSUs) rather than a market purchase or sale. Such grants are standard for directors and reflect compensation terms (subject to service-based vesting); they do not by themselves indicate the insider buying or selling shares on the open market.